Harnessing the Homing Nature of Stem Cells in a Targeted Drug Delivery Platform

NanoGhost is a biotech company that develops a highly selective first-in-class drug delivery platform (Nano-Ghosts/NGs) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation.

NGs are nanovesicles equipped with inherent MSC targeting capabilities, ability to infiltrate inter and intra cellular niches, with versatile loading capacity and broad therapeutic applicability.

 

This technology is based on 10 years of discoveries from the lab of Prof. Marcelle Machluf, Technion Institute of Technology, Israel.